{
  "docId": "019de071-38a0-778d-8d39-45a206af86ac",
  "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e",
  "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 69,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide outlines a clinical trial protocol involving 180 patients, stratified by condition and severity, with a 26-week duration and specific primary/secondary endpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/36",
  "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac",
  "deckJsonHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac.json",
  "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Clinical trial flow showing patient stratification, treatment arms, and adaptive enrichment steps.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc0cc252-410b-4429-8a13-6d5aaea3411e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.18,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "180 patients, Independent adjudication committee, Stratified for IMNM, ASyS, DM, Severity of muscle weakness (MMT), Eligibility criteria: Minimal muscle weakness, No malignancies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b0a2d1b-4317-4cfb-a4a8-7100031e4d54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.22,
        "x": 0.74,
        "y": 0.28
      },
      "kind": "list",
      "text": "Primary: Response based on Total Improvement Score (TIS), Key Secondary: Mean change and duration in TIS, Quality of Life, Individual Core Set Measures TIS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29ade657-b904-41d4-bf16-e47b040e071c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.23,
        "y": 0.83
      },
      "kind": "paragraph",
      "text": "IND filing by end of 2021 pending interaction with DCOA and CID division of FDA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc3bd70a-b22a-4486-9624-9e5ce0370ffe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Adaptive Phase 2/3 Enrichment Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2584526a-69fb-4ad8-ac04-7f59e57eecc5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "6a2b8bee-1ba2-406f-9062-9e7970f52a91",
      "evidence": "The slide describes a standard clinical trial protocol structure including patient population, stratification, treatment arms, and endpoints.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 43,
      "from": 29,
      "beatId": "002ee641-6d99-4db6-a151-22313bbe3e4f",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Data supporting Efgartigimod's effectiveness",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 43,
      "from": 29,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "2d58beec-e58f-42d6-98ee-47f2b7cb1adf",
      "evidence": "Data presentation and analysis",
      "position": 1,
      "objective": "Reveal the potential of Efgartigimod",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.8,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}